Study of IBI323 in Patients With Advanced Malignancies
NCT04916119
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
322
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Malignancies
Interventions
DRUG:
IBI323
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.